---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021346"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:56:20.472763+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma appoints new CMO, VP Clinical Ops; terminates CFO and COOs; submits GTX-104 Phase 3 plan to FDA

## Summary
- Appointed Dr. R. Loch Macdonald as CMO, Carrie D'Andrea as VP Clinical Ops, Amresh Kumar as VP Program Mgmt; effective immediately or May 15.
- Terminated CFO Brian Ford (interim until June 30), COO Canada Pierre Lemieux, COO US George Kottayil; severance payments.
- Submitted full protocol for GTX-104 pivotal Phase 3 Safety Study to FDA; first patient dosing expected Q4 2023.
- Strategic realignment focuses on GTX-104; cash runway extended through Q2 2025; evaluating alternatives for GTX-102, GTX-101.
- Discontinuing Canadian operations, laying off substantially all workforce; rebuilding leaner US organization.

## SEC filing metadata
- accession: 0000950170-23-021346
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/acst-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021346
- JSON: https://secwatch.observer/filing/0000950170-23-021346.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021346.txt

## Key facts
- Executive change
  Brian Ford was terminated as Chief Financial Officer at Grace Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm
- Executive change
  Amresh Kumar was appointed as VP of Program Management at Grace Therapeutics, Inc..
  - Action: appointed
  - Role: VP of Program Management
  source text: On May 8, 2023, the Company appointed Amresh Kumar, PhD, as its VP of Program Management, effective May 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm
- Executive change
  George Kottayil was terminated as Chief Operating Officer (US) at Grace Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Operating Officer (US)
  source text: On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm
- Executive change
  Dr. R. Loch Macdonald was appointed as Chief Medical Officer at Grace Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On May 8, 2023, the Company appointed Dr. R. Loch Macdonald, MD, PhD, as Chief Medical Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm
- Executive change
  Pierre Lemieux was terminated as Chief Operating Officer (Canada) at Grace Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Operating Officer (Canada)
  source text: On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm
- Executive change
  Carrie D'Andrea was appointed as VP Clinical Operations at Grace Therapeutics, Inc..
  - Action: appointed
  - Role: VP Clinical Operations
  source text: On May 8, 2023, the Company appointed Carrie D'Andrea as its VP Clinical Operations, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023021346/0000950170-23-021346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.